(NASDAQ: ATAI) Ataibeckley's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.27%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.89%.
Ataibeckley's earnings in 2026 is -$668,193,000.On average, 16 Wall Street analysts forecast ATAI's earnings for 2026 to be -$158,878,424, with the lowest ATAI earnings forecast at -$174,454,740, and the highest ATAI earnings forecast at -$144,080,924. On average, 14 Wall Street analysts forecast ATAI's earnings for 2027 to be -$173,267,973, with the lowest ATAI earnings forecast at -$203,530,530, and the highest ATAI earnings forecast at -$147,975,003.
In 2028, ATAI is forecast to generate -$173,379,233 in earnings, with the lowest earnings forecast at -$199,896,057 and the highest earnings forecast at -$147,975,003.